Brief: Positive Interim Phase 3 Results Highlight Potential Of Ovaprene®, Novel Hormone-Free Contraceptive

Dare Bioscience

12/05/2026 14:05

May 12 (Reuters) - Dare Bioscience Inc DARE.O:

POSITIVE INTERIM PHASE 3 RESULTS HIGHLIGHT POTENTIAL OF OVAPRENE®, NOVEL HORMONE-FREE CONTRACEPTIVE

DARE BIOSCIENCE INC - NO NEW ADVERSE EVENTS OR TOLERABILITY CONCERNS IDENTIFIED WITH OVAPRENE USE

DARE BIOSCIENCE INC - 12% OF PARTICIPANTS DISCONTINUED STUDY DUE TO VAGINAL ODOR, DOWN 5% FROM JULY 2025

DARE BIOSCIENCE INC - NO SERIOUS ADVERSE EVENTS RELATED TO OVAPRENE DEVICE IDENTIFIED

Source text: ID:nGNXqKPS1

Further company coverage: DARE.O

 ((Reuters.Briefs@thomsonreuters.com;))